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Abstract
T cell-mediated cancer immunotherapy is dose dependent and optimally requires participation of
antigen-specific CD4+ and CD8+ T cells. Here, we isolated tumor-sensitized T cells and activated
them in vitro using conditions that led to greater than 108-fold numerical hyperexpansion of either
the CD4+ or CD8+ subset while retaining their capacity for in vivo therapeutic efficacy. Murine
tumor-draining lymph node (TDLN) cells were segregated to purify the CD62Llow subset, or the
CD4+ subset thereof. Cells were then propagated through multiple cycles of anti-CD3 activation
with IL-2 + IL-7 for the CD8+ subset, or IL-7 + IL-23 for the CD4+ subset. A broad repertoire of
TCR Vβ families was maintained throughout hyperexpansion, which was similar to the starting
population. Adoptive transfer of hyper-expanded CD8+ T cells eliminated established pulmonary
metastases, in an immunologically specific fashion without the requirement for adjunct IL-2. Hyper-
expanded CD4+ T cells cured established tumors in intracranial or subcutaneous sites that were
not susceptible to CD8+ T cells alone. Because accessibility and antigen presentation within
metastases varies according to anatomic site, maintenance of a broad repertoire of both CD4+ and
CD8+ T effector cells will augment the overall systemic efficacy of adoptive immunotherapy.
Introduction
Cancer immunotherapy, using T lymphocytes that recog-
nize tumor-specific antigens, holds great promise. Advan-
tageous features include: exquisite specificity for targeted
antigens, thereby sparing normal tissues, and the ability of
effector T cells to traffic to tumor in all anatomic loca-
tions. Although most effector T cells are subject to activa-
tion-induced cell death (AICD), a memory response is
established leading to sustained protection [1]. Despite
the theoretical appeal of T cell-mediated immunotherapy,
clinically relevant benefits have been documented in only
a small subset of human cancer patients who present with
metastatic disease [2-5]. Several factors contribute to the
poor host immune response including defective Antigen
Presenting Cell (APC) function in cancer patients, and
production of immunosuppressive substances by tumors
[6-8].
Cognizant of these features, many preclinical studies of
active immunotherapy have used a vaccination/challenge
scheme to avoid tumor-induced immunosuppression or
have alternatively treated hosts with minimal tumor
Published: 26 November 2004
Journal of Translational Medicine 2004, 2:41 doi:10.1186/1479-5876-2-41
Received: 12 October 2004
Accepted: 26 November 2004
This article is available from: http://www.translational-medicine.com/content/2/1/41
© 2004 Wang et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Translational Medicine 2004, 2:41 http://www.translational-medicine.com/content/2/1/41
Page 2 of 12
(page number not for citation purposes)
burdens. Several human clinical trials have similarly
focused on hosts with minimal residual disease in order to
define the magnitude and characteristics of the immune
response. These studies have clearly established that
immune responses are successfully generated in vacci-
nated cancer patients. However, the frequency of respond-
ing T cells is typically less than one percent even after
multiple cycles of vaccination [9-14]. In contrast, the
immune response to pathogens generates a tremendous
amplification of reactive T cells [15-17]. In the clinical set-
ting, relatively little is yet known about the magnitude of
proliferation of individual precursor cells (burst size) as
they mature into effector cells, or the flux between lym-
phoid tissue, peripheral blood, and tumor sites. This
results in ambiguity about the optimal time and site to
quantify the immune response. Likewise, analysis of
apoptosis of effector cells is likely to be important [18,19].
These gaps in fundamental knowledge have made it diffi-
cult to identify components of active immunotherapy that
could be enhanced to boost the aggregate immune
response to a therapeutic level.
Adoptive immunotherapy is another approach to cancer
immunotherapy that circumvents some of the limitations
of active immunotherapy. Animal tumor models have
convincingly demonstrated that hosts bearing progres-
sively growing weakly immunogenic tumors nevertheless
generate sensitized T cells in TDLN [20]. Antigen-sensiti-
zation causes T cells to downregulate expression of L-
selectin (CD62L) providing a convenient phenotypic
marker for segregation of primed T cells from the majority
of irrelevant T cells [21-23]. Our previous studies have
demonstrated that ex vivo activation of purified CD62Llow
T cells from TDLNs generates potent effector CD4+ and
CD8+ T cells that can mediate regression of advanced
tumors in every tested anatomic location [24-26]. The
high potency of such cells permitted brief 5-day activation
and limited numerical amplification (10-fold) to supply
sufficient quantities of cells for the previous mechanistic
analysis of the anti-tumor response. Importantly, these
experiments demonstrated that there is tight dose depend-
ence, oftentimes with even a three-fold reduction in the
number of transferred cells accounting for a difference
between minimal treatment effect and complete cure. The
relative efficacy of CD4+ versus CD8+ effector cells also
varies considerably between pulmonary metastases and
intracranial (i.c.) or subcutaneous (s.c.) tumors [27]. This
indicates that maintenance of CD4+  as well as CD8+
tumor-reactive effector T cells would be required for opti-
mal adoptive immunotherapy against disseminated met-
astatic disease.
We investigated whether we could overcome quantitative
limitations associated with active immunotherapy
through extensive numerical expansion of effector cells. In
a previous study, we determined that in vitro activation of
tumor-sensitized L-selectinlow precursors with anti-CD3
mAb and high concentrations of IL-2 (100 U/ml) induced
rapid proliferation of CD8+ effector cells [28]. Adoptive
transfer of such cells cured established tumors in recipi-
ents. However, these culture conditions led to maximal
proliferation in 9 days with subsequent decline in cell
numbers thus limiting the total expansion to approxi-
mately 103-fold. In this report, we define ex vivo activation
conditions that permit numerical expansion of either
CD4+ or CD8+ effector T cells to greater than 108-fold
while retaining their high therapeutic potency and pre-
serving a broad T cell receptor (TCR) repertoire.
Materials and methods
Mice and tumors
Female C57BL6N (B6) mice were purchased from the bio-
logic Testing Branch, National Cancer Institute (Frederick,
MD). They were maintained in a specific pathogen-free
environment according to National Institute of Health
guidelines. Mice were used for experiments at 8–10 weeks
of age. The MCA 205 and MCA 207 fibrosarcomas, syn-
geneic to B6 mice were serially passaged in vivo s.c. as
described previously [29].
Preparation and culture activation of TDLN CD62Llow cells
Tumors were established by s.c. flank inoculation of 1.5 ×
106 MCA 205 cells and 12 days later the TDLNs were
removed and mechanically disrupted to obtain a single
cell suspension. The TDLN cells were incubated with 100
µl anti-CD62L microbeads per 108 cells and applied to
MACS columns (Miltenyi Biotech, Auburn CA) and the
flow through fraction was collected. For CD4+ hyperex-
pansion, the CD62Llow subset was depleted of CD8+ cells
by MACS on day 0 and day 36 of culture activation.
CD62Llow cells, containing approximately 50% TCR+ and
50% B220+ subsets, were suspended in complete medium
(CM) and incubated for 2 days at 4 × 106 per well in 24
well culture plates coated with anti-CD3 (145-2C11) as
previously described [28]. Activated cells were washed,
counted, and suspended at 0.5 × 105/ml in CM with IL-2
(4 U/ml) (Chiron Corp. Emeryville, CA), with or without
rmIL-7 (10 ng/ml) or rhIL-23 (2 ng/ml) (each from R&D
Systems, Minneapolis, MN) and then diluted to 105/ml
on day 5 of activation. On days 9 and 15, the cell concen-
tration was adjusted to 2 × 105/ml. For experiments with
two cycles of anti-CD3 stimulation, T cells were incubated
with immobilized anti-CD3 for 14 hrs on day 15 and used
for adoptive therapy on day 23. For long-term expansion,
cultures were maintained for 23 days after the initial anti-
CD3 stimulation in CM with the indicated combination
of IL-2 (4 U/ml), IL-7 (10 ng/ml), and IL-23 (2 ng/ml)
and then were stimulated with anti-CD3 for 14 hrs on day
23 and every 7 days thereafter.Journal of Translational Medicine 2004, 2:41 http://www.translational-medicine.com/content/2/1/41
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IFN-γ and FACS analysis
T cells were stimulated with a single cell suspension of
either MCA 205 or MCA 207 tumors at a 1:1 ratio, or with
immobilized anti-CD3. Brefeldin A was added after five
hours of stimulation and the cells were harvested after 20
hrs and stained for intracellular IFN-γ according to the
manufacturers instructions (BD Biosciences, San Diego,
CA). FACS analysis was performed using FITC or PE con-
jugated antibodies or isotype control antibodies (BD
Biosciences).
RNA isolation and CDR3 size distribution analysis (TCR 
spectratyping)
TDLN cells were lysed using TRIzol reagent (Invitrogen,
Carlsbad, CA) and total RNA was reverse transcribed into
cDNA using the SuperScript II RT kit (Invitrogen). cDNA
was amplified using PCR with 22 different VB-specific
primers paired with a hex-labeled constant region primer
which spans the CDR3 region as previously described
[30]. CDR3 size distribution analysis was performed by
mixing 1.0 µl of hex-labeled PCR amplified cDNAs with
12.0  µl deionized formamide (Sigma) and 0.5 µl size
standard (Genescan-400 ROX, ABI 310; Perkin-Elmer,
Shelton, CT), heated for 2 minutes at 90°C and chilled on
ice prior to analysis. Samples were applied to an ABI 310
sequencer for CDR3 size distribution analysis. Samples
were determined to be oligoclonally skewed if the CDR3
size patterns failed to exhibit a Gaussian bell-shaped dis-
tribution and were dominated by one or two prominent
peaks.
Adoptive immunotherapy
Mice were inoculated with MCA 205 or MCA 207 tumor
cells (3 × 105) i.v. to establish pulmonary metastases. Sub-
cutaneous tumors were established by inoculation of 1.5
× 106 cells. Intracranial tumors were established by tran-
scranial inoculation of 105 tumor cells at a depth of 4 mm
as previously described [31]. Mice bearing 3-day s.c. or i.c.
tumors or 10-day pulmonary metastases were treated with
5 Gy nonmyeloablative total body irradiation (TBI) deliv-
ered from a 137Cs irradiator prior to intravenous transfer
of the T cells whereas mice with 3-day pulmonary tumors
were not irradiated. For pulmonary tumors, mice were
euthanized on day 20 post inoculation, the lungs were
insufflated with India ink and the number of surface
tumor nodules was enumerated using a dissecting micro-
scope. Subcutaneous tumors were measured in two per-
pendicular dimensions three times per week and mice
with progressive tumors were euthanized when the prod-
uct of dimensions exceeded 200 mm2. Mice bearing
intracranial tumors were monitored daily for survival or
were euthanized when neurologic symptoms such as
decreased grooming and decreased spontaneous move-
ment were apparent.
Statistical analysis
Treatment groups consisted of five individuals. Analysis of
tumor size for s.c. tumors was performed by the Mann-
Whitney rank sum test. For pulmonary tumors, a t test was
performed on paired samples and p < 0.05 was considered
significant. Survival of mice bearing i.c. tumors was com-
pared using the Wilcoxon rank sum test.
Results
Ex vivo stimulation with anti-CD3, IL-2, and IL-7 augments 
effector cell generation
During the progressive growth of weakly immunogenic
tumors an immune response, albeit sub-therapeutic, is
initiated in TDLNs. In previous studies our laboratory has
demonstrated that the CD62Llow subset of T cells contains
the tumor-reactive subset whereas the reciprocal
CD62Lhigh subset does not have any therapeutic effect and
displays suppressor activity [1,24,32]. This finding is con-
sistent with numerous studies documenting the high
expression of CD62L on naïve T lymphocytes and its rapid
downregulation upon antigen stimulation [21-23].
TDLNs were harvested from mice bearing 12-day subcuta-
neous MCA 205 tumors and the CD62Llow subset was
purified by MACS depletion of CD62Lhigh cells. The typi-
cal yield of CD62Llow cells was 1.5 × 106 per TDLN, which
represented 7–8.5% of the initial cells. The phenotype of
the total TDLN prior to MACS separation and the nega-
tively selected CD62Llow subset is demonstrated in Figure
1A. The separated cells were highly enriched for the
CD62Llow fraction consisting of 36% TCR+ cells among
which 7% were CD8+ and 22% were CD4+. The cells were
activated with immobilized anti-CD3 mAb for 48 hrs dur-
ing which time aggregates of lymphoblasts developed.
The activated cells were resuspended at a low density, 0.5
× 105/ml, in medium supplemented with IL-2 (4 U/ml)
with or without IL-7 (10 ng/ml) and the cell concentra-
tion was adjusted to 105/ml on day 5 and 2 × 105/ml on
day 9. As demonstrated in figure 1B, there was an initial 2-
fold decline in cell number during the first 48 hrs of cul-
ture, primarily though depletion of CD62Llow B220+ cells.
This was followed by a rapid burst of proliferation from
day 2 until day 15 when the IL-2 supplemented culture
peaked at 175-fold proliferation and the IL-2 + IL-7 cul-
tures reached 1000-fold proliferation.
The morphology of the cells changed from lymphoblast-
oid to small round cells at day 15 and there was no addi-
tional proliferation. IL-7 preserved the viability of cells
whereas IL-2 alone could not prevent a 8-fold numerical
decline between days 15 to 30. Because the TDLN cells
were initially segregated based on phenotype rather than
antigen specificity and the anti-CD3 stimulation was anti-
gen-independent, it was not known whether the
enhanced proliferation achieved in the presence of IL-7
was due to preferential growth of irrelevant T cells orJournal of Translational Medicine 2004, 2:41 http://www.translational-medicine.com/content/2/1/41
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preservation of tumor-reactive T cells. As demonstrated in
figure 1C, there was equivalent therapeutic efficacy
against s.c. tumors at day 9 using T cells cultured with IL-
2 alone or the combination of IL-2 and IL-7. Regression of
established tumors requires efficient trafficking and the
dose of 5 × 106 CD62Llow TDLN cells is near the lowest
threshold dose required to cure 3-day s.c. MCA 205
tumors [26,33]. Thus, the addition of IL-7 during in vitro
activation augmented the total number of cells but did
not substantially diminish per-cell therapeutic efficacy.
Preservation of effector function after anti-CD3 re-
stimulation
The activated T cells were re-stimulated with anti-CD3 at
the time of maximal proliferation on day 15 to determine
whether additional numerical expansion could be initi-
ated. Re-stimulated cells rapidly regained lymphoblast
morphology and as anticipated nearly half of the cells
underwent AICD [34]. The surviving cells underwent a
100-fold numerical expansion before achieving a growth
plateau (Figure 2A). In addition, the composition of the T
Proliferation and efficacy of CD62LlowTDLN cells cultured with IL-2 +/- IL-7 Figure 1
Proliferation and efficacy of CD62Llow TDLN cells cultured with IL-2 +/- IL-7. (A) Freshly isolated whole TDLN cells 
were stained for expression of TCR and CD62L (left panel). The purified CD62Llow subset was stained for TCR and CD62L 
expression (center panel), or for CD4 and CD8 expression (right panel). (B) CD62Llow TDLN cells were activated with immo-
bilized anti-CD3 mAb for 2 days then cultured in medium with IL-2 (4 U/ml) (closed circle) or the combination of IL-2 and IL-
7 (10 ng/ml) (open circle). Cells density was adjusted to 105/ml on days 5 and 9 and total proliferation was calculated. (C) Mice 
bearing 3-day s.c tumors were treated with 5 Gy TBI then received adoptive transfer of 5 × 106 T cells cultured for 9 days with 
IL-2 alone (open circle), IL-2 + IL-7 (open triangle), or HBSS (closed circle). Each treatment group is significantly different than 
HBSS control (P < 0.01).
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cell cultures changed over time due to the more rapid
intrinsic proliferative response of CD8+  T cells [35].
Although CD4+ and CD8+ T cells each proliferated in the
presence of IL-2 and IL-7, by day 23 CD8+ cells comprised
86% of the culture whereas there were only 4% CD4+ cells
(Figure 2B). The re-stimulated cells cultured in IL-2 or the
combination of IL-2 plus IL-7 each retained potent thera-
peutic efficacy against 10-day MCA 205 pulmonary metas-
tases but not against MCA207, demonstrating retention of
antigenic specificity (Figure 2C). The hosts bearing 10-day
pulmonary tumors were treated with 5 Gy TBI, which
causes transient lymphopenia, prior to adoptive transfer.
Moreover, hosts did not receive adjunctive IL-2. Thus, the
transferred cells were able to function independently of
Restimulation of activated T cells induces additional proliferation with retention of specific anti-tumor efficacy Figure 2
Restimulation of activated T cells induces additional proliferation with retention of specific anti-tumor effi-
cacy. (A) CD62Llow TDLN cells were activated with anti-CD3 mAb from day 0–2 and again for 14 hrs on day 15. T cells were 
cultured in the presence of IL-2 (4 U/ml) (closed circle) or IL-2 plus IL-7 (10 ng/ml) (open circle) and the total proliferation is 
indicated. (B) FACS analysis of activated T cells on day 23 of culture stained for CD4 and CD8. (C) Mice bearing 10-day pulmo-
nary metastases of either MCA205 or MCA207 tumors were pre-treated with 5 Gy TBI then received adoptive transfer of 2.5 
× 107 cells cultured with IL-2 alone, the combination of IL-2 plus IL-7, or control HBSS as indicated. Difference between the 
groups bearing MCA 205 treated with T cells cultured with IL-2 or IL-2 plus IL-7 and all other groups is (P < 0.01). (D) Mice 
bearing 3-day s.c tumors were pre-treated with 5Gy TBI followed by injection of; HBSS (closed circles), 5 × 106 T cells acti-
vated for 5 days (open circles, P < 0.01), 5 × 106 restimulated T cells at day 23 of culture (closed triangles, P = 0.4), 1.5 × 107 
re-stimulated T cells (open triangle, P < 0.01), or 4 × 107 re-stimulated T cells (closed square, P < 0.01). Number of mice show-
ing complete regression in each treatment group of 5 mice is indicated in parentheses.
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radiosensitive host cells and were not dependent on exog-
enous cytokine support. Because the combination of IL-2
plus IL-7 promoted greater numerical expansion of CD8+
T cells with preservation of effector function, it was used
for subsequent hyperexpansion studies.
The relative per-cell potency of re-stimulated cultures on
day 23 was compared with the 5-day culture activation
approach we have employed in previous studies. The seg-
regated CD62Llow TDLN cells were frozen and one aliquot
was thawed and activated for a total of 23 days with anti-
CD3 stimulation on days 0–2 and again on day 15. The
second aliquot was thawed on culture day 18 of the first
aliquot and stimulated with anti-CD3 for 48 hrs and then
cultured with IL-2 and IL-7 for an additional 3 days. The
two T cell cultures were synchronously harvested and
transferred into hosts bearing 3-day s.c. tumors. As dem-
onstrated in Figure 2D, whereas 5 × 106 cells activated for
5 days was curative in 5/5 mice, 5 × 106 cells cultured for
23 days had minimal therapeutic effect. However, a mod-
est increase in the cell dose to 1.5 × 107 cells led to a sig-
nificant therapeutic effect and at a dose of 4 × 107 cells 2/
5 mice were cured. The s.c. tumor model is highly depend-
ent on the presence of tumor-specific CD4+ T cells [36,37].
The relative decrease in percentage of CD4+ cells from
24% on day 5 of culture to 4% on day 23 may account for
some of the differential therapeutic effects. In contrast to
the modest difference in per-cell efficacy, there was nearly
1000-fold greater proliferation in the 23-day versus 5-day
cultures indicating that the aggregate therapeutic effect
was substantially greater following extended culture.
Repetitive anti-CD3 stimulation induces hyper-expansion 
of CD8+ effectors
There are immunologic scenarios that demonstrate
exhaustion of the effector response leading to failure of
immunologic control of infection or tumor [38-40]. By
contrast, selection and extensive propagation of T cell
clones indicates that T cells can undergo massive prolifer-
ation yet retain antigen-specific function. To assess
whether there is an intrinsic limit to the retention of in
vivo effector function of CD62Llow cells, they were stimu-
lated with anti-CD3 followed by IL-2 and IL-7 for 23 days.
Starting on day 23, the T cells were activated with anti-
CD3 every 7 days. The time course between the initial and
subsequent anti-CD3 stimulations was chosen based on
evidence that T cells undergo changes in gene expression,
phenotype, and function over a twenty-day time course in
the transition from naïve to memory cells [41].
As demonstrated in Figure 3A, repetitive anti-CD3 stimu-
lation was accompanied by immediate AICD in approxi-
mately 50% of the cells followed by rapid proliferation.
There was no evidence that the T cells became effete over
the 50-day expansion period despite a total proliferation
of 2–6 × 108-fold that was consistent in three independent
experiments. TCR Vβ expression was determined for
freshly harvested TDLN T cells, the CD62Llow subset, and
activated cultures from several independent experiments
(Table 1) "see additional file 1". As demonstrated, multi-
ple TCR Vβ families are represented prior to and following
hyperexpansion. There is a relatively low level of variabil-
ity in the prevalence of multiple TCR Vβ families between
experiments, especially considering that greater than 108-
fold total proliferation had occurred. In addition, TCR
spectratype analysis for each Vβ family revealed a poyclo-
nal rather than clonal or oligoclonal distribution (data
not shown).
At day 50, the cultures were >99% TCR+ and CD8+ indicat-
ing preferential expansion or survival of CD8+ cells under
the conditions employed. As shown in Figure 3B, adop-
tive transfer of 2 × 107 cells to hosts with 3-day MCA205
pulmonary metastases eliminated tumors and 6 × 106
cells was the threshold dose for complete response
whereas 2 × 106 cells were subtherapeutic. In addition,
there was no response against the antigenically distinct
MCA207 tumor. In an independent experiment, the dose
of T cells required to completely eliminate 3-day pulmo-
nary metastases was 2 × 106 indicating some inter-experi-
mental variability in per-cell efficacy. Because of the
critical role of CD4+ T cells for therapy of s.c. or i.c. tumors
it was not anticipated that the hyperexpanded CD8+ cul-
tures would mediate complete regression of tumors at
these anatomic sites. Indeed, there was substantially less
efficacy against 3-day s.c.tumors. Adoptive transfer of 4 ×
107 cells showed a trend toward response (P = 0.061) with
1/5 mice cured in only one of two identically designed
experiments (Figure 3C). In addition, a dose of 2 × 107
cells was subtherapeutic against 3-day i.c. tumors (Figure
3D).
Despite the rapid proliferation of CD8+ T cells in vitro,
there was no evidence of lymphoid hyperplasia when the
mice were sacrificed to enumerate lung metastases 17 days
after adoptive transfer. Moreover, there was no evidence
of lymphoproliferative disease even when the
hyperexpanded T cells were transferred into 5Gy TBI hosts
bearing i.c. or s.c. tumors that had transient lymphodeple-
tion of host cells. Thus, despite extensive proliferation in
vitro  the T cells did not demonstrate any evidence of
transformation.
Hyperexpanded CD4+ T effector cells mediate regression 
of i.c. and s.c. tumors
The clinical utility of adoptive immunotherapy for
patients with metastatic cancer is dependent on the ability
of T cells to function at all anatomic sites of disease. To
selectively activate CD4+ T cells, the CD62Llow TDLN were
depleted of CD8+ cells with magnetic beads prior to anti-Journal of Translational Medicine 2004, 2:41 http://www.translational-medicine.com/content/2/1/41
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CD3 activation and again on day 36 of culture. The CD4+
cells were activated with anti-CD3 mAb for 48 hrs and
cultured in the presence of IL-7 and either IL-2 or IL-23
with anti-CD3 restimulation performed on days 26 and
day 36 of culture. The rate of proliferation of CD4+ cells
was similar in the presence of IL-2 or IL-23 (Figure 4A).
On day 43 of culture, cells cultured with IL-7 plus IL-2
were 87% CD4+ and 11% CD8+, whereas cells cultured in
IL-7 plus IL-23 were 98% CD4+ and less than 1% CD8+.
The T cells were adoptively transferred to hosts with 3-day
s.c (Figure 4B) or 3-day i.c. (Figure 4C) tumors demon-
strating that a dose of 3 × 107 cells cultured in the presence
of either IL-2 or IL-23 was curative.
The CD4+ T cells maintained in IL-7 plus IL-23 were sub-
jected to continued repetitive anti-CD3 restimulation
every 7 days starting on day 56. These conditions led to
exclusive proliferation of CD4+ T resulting in 1.2 × 108-
CD8+ effector T cells can be hyperexpanded through repetitive anti-CD3 stimulation Figure 3
CD8+ effector T cells can be hyperexpanded through repetitive anti-CD3 stimulation. (A) CD62Llow TDLN cells 
were restimulated with anti-CD3 mAb for 14 hrs every 7 days starting on day 23 of culture and overall proliferation was meas-
ured for three independent experiments. (B) T cells were harvested on day 50 of culture and adoptively transferred to hosts 
bearing either MCA 205 or MCA 207 3-day pulmonary metastases (P < 0.01 for MCA 205 tumors treated with either 6 × 106 
or 2 × 107 compared with all other groups). (C) Mice bearing 3-day s.c tumors were treated with 5 Gy TBI then received adop-
tive transfer of the indicated number of T cells hyperexpanded for 50 days (P = 0.06 for 4 × 107 cell dose) (D) Mice bearing 3-
day i.c. tumors were treated with 5Gy TBI then received adoptive transfer of the indicated number of T cells hyperexpanded 
for 50 days. Mice were sacrificed when they developed neurologic symptoms indicating progressive tumor (P = 0.9 for treat-
ment groups versus control).
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Hyperexpanded CD4+ T cells mediate regression of intracranial or subcutaneous tumors Figure 4
Hyperexpanded CD4+ T cells mediate regression of intracranial or subcutaneous tumors. (A) CD62Llow TDLN 
cells were depleted of CD8+ cells prior to anti-CD3 activation and were maintained in medium with IL-2 (4 U/ml) plus IL-7 (10 
ng/ml) or alternatively with IL-7 (10 ng/ml) plus IL-23 (2 ng/ml) and were restimulated for 14 hrs with anti-CD3 mAb at the 
indicated time points. The total proliferation with indicated losses due to AICD or re-purification of CD4+ cells is indicated. (B) 
Mice bearing 3-day s.c.tumors were treated with 5 Gy TBI followed by adoptive transfer of 3 × 107 CD4+ T cells culture acti-
vated for 43 days and tumor size was measured. On day 37, one mouse from IL-2 + IL-7 group was euthanized due to progres-
sive tumor growth, however complete regression was observed in the remaining 4 mice (P = 0.015 versus control). Complete 
regression was observed in all five recipients of IL-7 + IL-23 cultured CD4+ T cells (P = 0.005 versus control). (C) Mice bearing 
3-day intracranial tumors were treated with 5Gy TBI followed by adoptive transfer of 3 × 107 CD4+ T cells culture activated 
for 43 days. Mice were followed for survival (P < 0.01 for both treatment groups versus control). (D) Mice bearing 3-day sub-
cutaneous tumors were treated with 5 Gy TBI followed by adoptive transfer of 4 × 107 CD8+ T cells hyperexpanded to greater 
than 108-fold for 50 days, or 1.5 × 107 CD4+ T cells hyperexpanded to greater than 108-fold for 85 days. On day 28, 4 mice 
from CD8 treatment group (* P = 0.39 versus control) and 2 mice from CD4 treatment group (# P = 0.019 versus control) 
were euthanized due to progressive tumor growth but complete tumor regression was observed in the remaining mice.
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fold total proliferation by day 85 of culture. Despite exten-
sive in vitro proliferation in response to antigen-independ-
ent stimulation for 85 days, 1.5 × 107 CD4 cells retained
efficacy against 3-day s.c.tumors, with 3/5 mice achieving
complete tumor regression (P = 0.019 versus control)
(Figure 4D). As previously demonstrated, CD8+ cells syn-
chronously cultured in the presence of IL-2 plus IL-7 for
50 days and expanded to 108-fold demonstrated minimal
efficacy against subcutaneous tumors (P = 0.39 versus
control) with 1/5 mice achieving complete tumor
regression.
Hyperexpanded cultures retain IFN-γ producing cells
The initial antigen priming event in vivo was driven by
tumor-specific antigens but the segregation of the
CD62Llow subset and all subsequent in vitro activation
stimuli were antigen independent. Consequently, reactiv-
ity of cultures against tumor antigens might fluctuate over
time. This possibility was analyzed by quantifying the per-
centage of culture activated T cells that produce IFN-γ spe-
cifically when exposed to tumor in vitro. For this assay, a
single cell digest of in vivo propagated tumor is used which
contains MHC class II+ APC as well as tumor cells and is
capable of stimulating both CD4+ and CD8+ T cells. As
demonstrated in Figure 5, there was minimal spontane-
ous production of IFN-γ and minimal reactivity against
the antigenically distinct MCA 207 tumor. By contrast, on
day 8 of culture 39% of CD8+ T cells produced IFN-γ in
response to MCA 205 tumor cells. This percentage of IFN-
γ positive CD8+ cells decreased to 10% on day 36. CD8+ T
cells that were simply maintained in culture with IL-2 and
IL-7 cytokine support but without anti-CD3 restimulation
did not proliferate but remained viable. Under non-prolif-
erative conditions, the percentage of MCA 205 reactive T
cells was maintained at 13% on day 36. Similarly, CD4+ T
cells cultured in the presence of IL-7 plus IL-23 had 11%
IFN-γ positive cells in response to MCA205 tumor with
minimal spontaneous production and minimal response
to MCA207 tumor digest. The in vitro assay of IFN-γ
production may not be fully reflective of the in vivo capac-
ity of T cells to mediate tumor regression because CD4+ T
cells cultured with IL-2 plus IL-7 had only 2% IFN-γ posi-
tive cells despite equivalent in vivo anti-tumor efficacy.
The vast majority of T cells (73–86%) produced IFN-γ in
response to anti-CD3 stimulation throughout the in vitro
culture activation period.
Discussion
These experiments demonstrate that T cells, sensitized to
tumor antigens in vivo, can be activated in vitro under con-
ditions that promote hyperexpansion of either the CD4+
or CD8+ subset while retaining their potent therapeutic
efficacy against established tumors. A notable feature of in
vitro activation is that it permits selection and enrichment
of a minor subset of tumor-reactive precursor cells. The
mechanism of antigen sensitization of T cells through
cross-priming by APC within draining LNs provides a
convenient localized anatomic source that is already
highly enriched. When coupled with physical segregation
based on phenotypic characteristics that distinguish
between antigen-stimulated versus naïve T cells, enrich-
ment to nearly 40% of tumor-specific T cells was achieved.
One important aspect of this strategy for selection and
enrichment is that it does not require pre-existing knowl-
edge of the immunogenic tumor antigens and does not
require freshly acquired T cells to exhibit effector function.
These conditions have relevance for many clinical situa-
tions where tumor antigens are not yet described or where
unique tumor antigens may be immunodominant. More-
over, signaling defects have been observed in freshly
acquired T cells from tumor-bearing hosts that might
impede segregation based on functional properties [42-
44].
Starting with a highly enriched population of T cells we
were able to use a powerful, yet antigen-independent,
Hyperexpanded CD4+ and CD8+ T cells produce IFN-γ in  response to tumor stimulation Figure 5
Hyperexpanded CD4+ and CD8+ T cells produce IFN-
γ in response to tumor stimulation. CD62Llow TDLN 
cells were culture activated with anti-CD3 and IL-2 plus IL-7 
for 23 days then were restimulated with anti-CD3 every 7 
days. T cells were removed from culture on day 8, on day 36 
for CD8+ cultures, or day 43 for CD4+ cultures. T cells were 
incubated without additional stimulus to determine sponta-
neous production of IFN-γ or with single cell digest of 
MCA205 or MCA207 tumors or with immobilized anti-CD3 
mAb and Brefeldin A was added at 5 hrs and cells were har-
vested after 14 hrs. Intracellular IFN-γ was determined by 
FACS and the percentage of T cells is indicated.
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stimulus such as anti-CD3 mAb that preserved the initial
TCR repertoire diversity. Interestingly, anti-CD28 stimula-
tion was not required for this experimental model,
presumably because the T cells had already received co-
stimulation during APC-mediated priming in vivo. The
principal advantage to in vitro activation is that the culture
conditions can be adapted to optimize proliferation of
distinct subsets of responding cells. It is important to note
that anti-CD3 activation in the absence of exogenous
cytokine support did not lead to T cell proliferation even
among CD4+ cells. The low cell density may have pre-
vented secreted cytokines from reaching a critical thresh-
old concentration. Moreover, IL-7, produced by non-
hematopoetic cells and IL-23, produced by APC, man-
dated an exogenous source of these cytokines for in vitro
culture activation. The combination of IL-2 and IL-7 pro-
vided rapid proliferation of CD8+ T cells and preserved
their viability after completion of the initial mitogenic
burst. The reason this combination was effective is that IL-
7 receptor α chain is constitutively expressed on naïve and
memory T cells but is downregulated on activated T cells
[45,46]. By contrast, the IL-2 receptor α chain is recipro-
cally expressed on activated cells in a transient manner.
Thus, the combination of these two cytokines ensured
continuous mitogenic signal transduction. IL-7 is crucial
for development and homeostasis of T cells and is mark-
edly increased following lymphodepletion. Therefore,
there is considerable interest in employing lymphodeple-
tion as a strategy to augment active as well as adoptive
immunotherapy [47]. Likewise, exogenous IL-2 has been
administered in the context of tumor antigen vaccination
as well as in nearly every clinical application of adoptive
transfer to provide helper function [48]. However, in
addition to their mitogenic effects on antigen-stimulated
T cells, systemic production of IL-7 or systemic adminis-
tration of IL-2 has effects on irrelevant T lymphocytes,
other hematopoetic cells, and the vasculature. The inabil-
ity to target cytokine support specifically to the relevant T
cells limits the effectiveness of in vivo cytokine administra-
tion. More importantly, we have clearly documented that
adjunctive IL-2 inhibits trafficking of adoptively trans-
ferred T cells into intracranial or subcutaneous tumors
[49]. By contrast, cytokine stimulation can be targeted
specifically to effector cells under optimal conditions in
vitro without adverse systemic effects on the host. Future
experiments to adjust the sequence, and concentration of
supplemental cytokines using more sophisticated sched-
ules than employed here might provide superior effector
function.
These experiments confirm the importance of CD4+ T cells
for therapy of tumors in certain anatomic sites, such as the
brain and subcutaneous tissue. The slower rate of CD4+
cell proliferation relative to CD8+ cells following the ini-
tial anti-CD3 stimulation led to their rapid marginaliza-
tion in mixed cultures. However, depletion of CD8+ cells
and use of cytokine combinations such as IL-7 and IL-23
favored the selective hyperexpansion of CD4+ cells that
retained potent in vivo function. IL-23 is a member of the
IL-12 family of cytokines and contains the IL-12 p40 sub-
unit that transduces signals through the shared IL-12β1
chain in addition to the unique p19 subunit [50,51]. The
IL-23 receptor is expressed on memory but not naive
CD4+ cells, thus it is ideal for previously sensitized LN T
cells. Myeloid cells, which are the natural source of IL-23,
disappear rapidly in the in vitro cultures mandating an
exogenous source. There is not a substantial amount of
data on the effects of in vivo IL-23 administration, there-
fore its utility as a systemically administered adjuvant for
T cell adoptive immunotherapy is unclear. However, the
related cytokine IL-12 has substantial systemic effects that
have limited its clinical use [52].
Although CD4+ T cells have been investigated as a source
of helper function for CD8+ cytolytic cells our previous
experiments have clearly established their stand-alone
potential against MHC class II negative tumors [53]. CD4+
T cell anti-tumor function is mediated through cross-pres-
entation of specific tumor-antigens by tumor associated
APC [54]. As demonstrated, CD4+ cells cultured with IL-
23 produced greater levels of INF-γ that would augment
antigen presentation. Indeed, addition of tumor-reactive
CD4+ cells to tumor digest increases the reactivity of the
CD8+ cells. In addition to their autonomous effector func-
tions, CD4+ cells are required to generate a functional
CD8+ memory response in vivo [55,56]. Our recent exper-
iments have demonstrated that adoptive transfer of effec-
tor T cells causes tumor destruction and sensitization of a
secondary wave of regenerating host T cells [57]. In this
regard, IL-23 stimulation of CD4+ cells might be particu-
larly useful because it, unlike IL-12, induces production of
the pro-inflammatory cytokine IL-17 [58]. Our observa-
tion that such sensitization occurred even in hosts with
partial tumor regression indicates that the presence of
effector CD4+ T cells and inflammatory conditions of
tumor antigen acquisition by host APC are important in
perpetuating the anti-tumor response.
Repetitive anti-CD3 stimulation was utilized to drive
hyperproliferation of T cells yet the TCR/CD3 complex
also activates genetic programs required for effector func-
tion. Effector molecules such as Fas, Perforin, and IFN-γ
have autoinhibitory as well as paracrine inhibitory effects
during culture activation. Viewed purely in operational
terms, sequential in vitro activation first under conditions
that optimize T cell proliferation, then with conditions
that restore effector functions immediately before adop-
tive transfer, would be advantageous. Future experiments
will explore whether it is possible to dissociate prolifera-
tive signaling pathways from those mediating effectorJournal of Translational Medicine 2004, 2:41 http://www.translational-medicine.com/content/2/1/41
Page 11 of 12
(page number not for citation purposes)
function through selective transient gene inactivation. The
quantitative aspects of hyperexpansion are of less scien-
tific interest but do have some practical implications. The
108-fold extent of proliferation far exceeded what was
required to treat the tumor models employed. Moreover,
the availability of uniformly primed T cells for mechanis-
tic studies is not numerically limited when using an
inbred strain. However these experiments establish an
approach to maintain polyclonality and preserve effector
function despite extensive antigen-independent prolifera-
tion. As such, the quantitative aspects of hyperexpansion
may have relevance to certain clinical situations where an
autologous source of antigen-primed T cells may be lim-
ited and extensive host tumor burden may demand a large
number of effector T cells.
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